In addition to pulmonary fibrosis, columnist Ann Reynoso is now also dealing with sleep apnea — both of which affect her ...

Among patients with PPF, those treated with 60 mg of admilparant showed significant decreases in periostin, ferritin, and ...

The positive phase 3 results showed improved lung function with nerandomilast vs placebo at 52 weeks in idiopathic pulmonary ...

This blog describes a typical ILD patient journey from the initial diagnosis through its long-term management to end-of-life ...

Ioannis Sapountzis, head of global therapeutic areas at Boehringer, said that FIBRONEER-IPF is the largest trial in IPF ...

R&D image Topline data from FIBRONEER™-IPF show that the investigational compound nerandomilast met its primary endpoint, ...

Millions of people in the U.S. are living with lung diseases such as asthma, chronic obstructive pulmonary disease (COPD), pulmonary fibrosis and pulmonary arterial hypertension (PAH).

Topline data from FIBRONEER-IPF show that the investigational compound nerandomilast met its primary endpoint, which was the absolute change from baseline in Forced Vital Capacity [mL] at week 52 vers ...

Boehringer Ingelheim pivotal phase-III FIBRONEER-IPF study of nerandomilast meets primary endpoint: Ingelheim, Germany Tuesday, September 17, 2024, 13:00 Hrs [IST] Boehringer Inge ...

National Youth Tobacco Survey e-cigarette and nicotine pouch data from the U.S. Food and Drug Administration (FDA) and the ...